Targeting quiescent leukemic stem cells using second generation autophagy inhibitors

In chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) treatment induces autophagy that promotes survival and TKI-resistance in leukemic stem cells (LSCs). In clinical studies hydroxychloroquine (HCQ), the only clinically approved autophagy inhibitor, does not consistently inhibit autoph...

Descripción completa

Detalles Bibliográficos
Autores principales: Baquero, Pablo, Dawson, Amy, Mukhopadhyay, Arunima, Kuntz, Elodie M., Mitchell, Rebecca, Olivares, Orianne, Ianniciello, Angela, Scott, Mary T., Dunn, Karen, Nicastri, Michael C., Winkler, Jeffrey D., Michie, Alison M., Ryan, Kevin M., Halsey, Christina, Gottlieb, Eyal, Keaney, Erin P., Murphy, Leon O., Amaravadi, Ravi K., Holyoake, Tessa L., Helgason, G. Vignir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292500/
https://www.ncbi.nlm.nih.gov/pubmed/30185934
http://dx.doi.org/10.1038/s41375-018-0252-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292500/
https://www.ncbi.nlm.nih.gov/pubmed/30185934
http://dx.doi.org/10.1038/s41375-018-0252-4

Ejemplares similares